BTAI – bioxcel therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs [Yahoo! Finance]
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering [Yahoo! Finance]
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Mehta Vimal
Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Steinhart Richard I
Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Rodriguez Javier
Form 4 BioXcel Therapeutics, For: Mar 14 Filed by: Yocca Frank
Form 8-K BioXcel Therapeutics, For: Mar 10
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.